196487
4-Biphenylacetic acid
98%
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
C6H5C6H4CH2CO2H
CAS Number:
Molecular Weight:
212.24
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
227-233-2
MDL number:
Assay:
98%
Related Categories
General description
4-Biphenylacetic acid is a potential non-steroidal antiinflammatory agent and forms solid inclusion complex with β-cyclodextrin. 4-Biphenylacetic acid on interaction with quinolone antibacterial agents induces functional blockade of the γ-aminobutyric acid receptors.
Application
4-Biphenylacetic acid was used in the synthesis of gastrosparing non-steroidal antiinflammatory drug.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K Akahane et al.
Antimicrobial agents and chemotherapy, 38(10), 2323-2329 (1994-10-01)
The combination of some new quinolone antibacterial agents with 4-biphenylacetic acid (BPAA), a metabolite of fenbufen, is known to specifically induce functional blockade of the gamma-aminobutyric acid (GABA) receptors. The mechanisms of these drug interactions were further examined. Scatchard analysis
G Puglisi et al.
The Journal of pharmacy and pharmacology, 43(6), 430-432 (1991-06-01)
4-Biphenylacetic acid, a potent non-steroidal anti-inflammatory agent forms a solid inclusion complex with beta-cyclodextrin in a 1:1 molar ratio, which exhibits better solubility and dissolution characteristics than the uncomplexed drug. Following oral administration of the complex to rats, quicker and
Chao Zhang et al.
Journal of pharmaceutical and biomedical analysis, 50(1), 41-45 (2009-04-21)
A rapid and sensitive analytical method based on high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed for the determination of felbinac in rat plasma, bile, urine, feces and tissue. Sample preparation involved liquid-liquid extraction with ethyl ether-dichloromethane (60:40, v/v).
Chao Zhang et al.
Xenobiotica; the fate of foreign compounds in biological systems, 41(4), 340-348 (2010-12-25)
Felbinac trometamol (trishydroxymethylaminomethane 4-biphenylacetate) is a new water-soluble salt of felbinac currently undergoing clinical evaluation as an intravenous (i.v.) formulation for the treatment of severe post-operative pain. This article reports the pharmacokinetics of felbinac after i.v. administration of felbinac trometamol
Mamta Madhukar et al.
European journal of medicinal chemistry, 45(6), 2591-2596 (2010-03-17)
A novel mutual prodrug consisting of 4-biphenylacetic acid (BPA) and quercetin tetramethyl ether (QTME) has been synthesized as a gastrosparing NSAID, devoid of ulcerogenic side effects. The physicochemical properties, including aqueous solubility, partition coefficient, chemical stability and enzymatic hydrolysis of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service